Study identifies genes associated with risk of triple-negative breast cancer

Questions To Ask Your Health Care Provider

• Should I consider genetic testing?
• Can you refer me to a genetics expert?
• I had BRCA testing which was negative. Should I consider panel testing?
• Are there different risk management strategies that would benefit me?
• Are there targeted treatments that are appropriate for me?

Open Clinical Trials

The following studies are enrolling people with early-stage TNBC.  

• NCT05629585: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03). This study evaluates the safety and effectiveness of the investigational drug Dato-DXd given with or without durvalumab when compared with the combination capecitabine and/or pembrolizumab in people with stage 1-3 TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
• NCT04584255: Treating Early-Stage BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab). This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations.
• NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. This study determines the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple-negative breast cancer.
• NCT03562637: Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC. The GLORIA study is a Phase III, randomized trial investigating the use of the drug adagloxad simolenin (OBI-822) in combination with the drug OBI-821 for adjuvant treatment of patients with high-risk, early-stage TNBC.
• NCT05455658: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer. This trial studies the effect of the STEMVAC vaccine to treat patients with patients with stage 2B-3 triple-negative breast cancer.
• NCT05929768: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer. This study compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to the standard chemo-immunotherapy for the treatment of early-stage triple-negative breast cancer. 

Several other clinical trials for patients with early-stage TNBC can be found here.

The following clinical trials include genetic counseling and testing. 

• NCT02620852: WISDOM Study: Women Informed to Screen Depending on Measures of Risk offers women ages 40-74 the opportunity to undergo risk assessment and genetic testing in order to determine the best breast screening options based on their situation.  
• NCT05562778: Chatbot to maximize hereditary cancer genetic risk assessment. Researchers are testing whether a mobile health platform, known as a "chatbot" can improve rates of genetic testing among Medicaid patients with an elevated risk having an inherited mutation.
• NCT05427240: eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer (eReach2). This study will look at the effectiveness of offering web-based options for pre/post-test genetic counseling to provide equal or improved timely uptake of genetic services and testing. 
• NCT05694559: Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics. This study will provide genetic testing to 150 Black individuals and families and provide genetic counseling and risk reduction resources to individuals with a mutation linked to increased cancer risk.

Other genetic counseling or testing studies may be found here.